At a glance

ClinicalIndex Comparison Record

Phase 2Completed· 44 enrolled

Drug / intervention

Placebo taken first +4 moredrug

Likely dose

Not stated in record

Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01759446

NCT01759446Phase 2Completed

Compare CT.gov

A Single-center, Randomized, Double-blind, Active- and Placebo Controlled, 5-way Crossover Study Assessing the Abuse Potential of Intranasally Administered VYCAVERT Tablets in Non-dependent Recreational Opioid Users.

Acura Pharmaceuticals Inc.·interventional·Posted Jan 3, 2013·Updated Nov 1, 2018

In Brief

A Phase 2 clinical trial evaluating Placebo taken first, Generic H/A taken first, and 3 other interventions for Opioid-Related Disorders. Completed, enrolled 44 participants across 1 site.

Detailed Summary

To determine the relative abuse potential of VYCAVERT (hydrocodone bitartrate and acetaminophen) compared to GENERIC H/A (hydrocodone bitartrate and acetaminophen) when crushed and administered intranasally to non dependent, recreational opioid users.

Study Details

Study Typeinterventional

Allocation--

Masking--

Primary Purpose--

ConditionsOpioid-Related Disorders

CountriesUnited States

Collaborators--

Timeline

Phase 2CompletedFinished

20132014201520162017201820192020202120222023202420252026

First PostedJan 2013

Enrollment StartFeb 2013

Primary CompletionApr 2013

TodayJul 2026

First PostedJan 3, 2013

Enrollment StartFeb 1, 2013

Primary CompletionApr 1, 2013

TodayJul 2, 2026

Enrollment to primary: 2 monthsPosted 13.5 years ago